Dermatology | Phase III Developments | JAPAN

Chugai Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Onl...

Lead Product(s): Nemolizumab

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai.

Otsuka Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36

Lead Product(s): Difamilast

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

Difamilast (OPA-15406) me primary end points in patients with atopic dermatitis, in both the adult and pediatric trials.

Torii Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

JT to market CORECTIM in Japan to treat atopic dermatitis

Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Under the terms of the agreement on October 2016nbetween JT and Torii, the drugs will be sold exclusively by Torii in Japan, following itsninclusion in the National Health Insurance (NHI) price list.

Find

Find Dermatology Drugs in Phase III Clinical Development in JAPAN

Japan

Product Type

Companies

Chugai Pharmaceutical

Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Onl...

Otsuka Pharmaceutical

Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36

Torii Pharmaceutical

JT to market CORECTIM in Japan to treat atopic dermatitis